Cancer Stem Cells: Targets for treatment of malignancies to overcome drug resistance A Review of Well-designed HIS
Archives of Advances in Biosciences,
Vol. 12 No. 2 (2021),
9 Ordibehesht 2021
,
Page 67-84
https://doi.org/10.22037/aab.v12i2.32482
Abstract
Context: Cancer is one of the mortal diseases all around the world and despite all advancements in designing effective anticancer drugs, most tumors have been found to relapse, metastasize to another organs and cause resistance to therapy. Cancer stem cells (CSCs) which are a small population of cancer cells, due to their ability to self-renew and differentiate into heterogeneous cancer cells are thought to be responsible for cancer recurrence and anticancer treatment resistance.
Evidence Acquisition: Studies indicate that different molecular mechanisms like signaling pathways, cell surface markers, tumor microenvironment and miRNAs are involved in drug resistance property of cancer stem cells. Hence, having a good knowledge of these mechanisms could help in finding an effective therapeutic strategy to target the cancer stem cells in order to overcome the issue of tumor relapse and drug resistance.
Results: Taken together, cancer stem cells use various mechanisms to escape from immune system and other defensive obstacles like apoptosis to survive and induce drug resistance. This fact emphasizes the need for combination therapies in addition to targeting each aspect of these cells.
Conclusion: It seems reasonable to conclude that, finding effective ways to eliminate chemotherapy resistance needs more research and clinical trials in different cancers using various strategies targeting cancer stem cells’ properties.
- Cancer Stem Cells, Marker, Cell Signaling, Drug Resistance, Cancer Treatment
How to Cite
References
Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018; 2018:5416923
Ayob AZ , Ramasamy TS.Cancer stem cells as key drivers of tumour progression.Journal of Biomedical science. 2018; 25(20).
Papaccio F, Paino F , Regad T, Papaccio G, Desiderio V , Tirino V.Concise Review: Cancer Cells, Cancer Stem Cells,and Mesenchymal Stem Cells: Influence in Cancer Development.Stem Cells Translational Medicine. 2017; 6:2115–2125.
Prieto-Vila M, Takahashi R-U, Usuba W, Kohama I , Ochiya T.Drug Resistance Driven by Cancer Stem Cells and Their Niche. International Journal of Molecular Sciences. 2017;18(2574).
Kuşoğlu A, Biray Avcı Ç. Cancer stem cells: A brief review of the current status.Gene . 2019; 681:80-85.
Iseghohi SO,.Cancer stem cells may contribute to the difficulty in treating cancer.Genes & Diseases. 2016; 3: 7-10.
Yadav A , Desai N. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.Stem Cell Reviews and Reports. 2019; 15(3):331-355.
Prasad S, Ramachandran S, Gupta N, Kaushik I , Srivastava S.K.Cancer cells stemness: A doorstep to targeted therapy.BBA-Molecular Basis of Disease. 2020 ;1866(4):165424.
Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer.Journal of Cellular Physiology. 2018;1-9.
Sun JH, Luo Q, Liu LL , Song GB.Liver cancer stem cell markers: Progression and therapeutic implications.World Journal of Gastroenterology. 2016; 22(13):3547-3557.
Zakaria N, Abdul Satar N, Abu Halim NH, Ngalim SH, Yusoff NM, Lin J et al.Targeting Lung Cancer Stem Cells:Research and Clinical Impacts.Frontiers in Oncology. 2017; 7(80): 1-10.
Caras I. Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.Stem Cells Translational Medicine. 2020; 1-6.
Kumar A , Bhanja A , Bhattacharyya J , Jaganathan BG.Multiple roles of CD90 in cancer.Tumor Biol. 2016; 37(9):11611-11622.
J. Agorku D, Langhammer A , Heider U , Wild S, Bosio A , Hardt O.CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models.Frontiers in Oncology. 2019; 9(716): 1-13.
von Lersner A, Lenny Droesen L, Zijlstra A. Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166.Clin Exp Metastasis. 2019;36(2):87-95.
Lertkiatmongkola P, Liaoa D, Meib H, Hub Y, J. Newmana P.Endothelial functions of PECAM-1 (CD31).Curr. Opin .Hematol. 2016; 23(3):253-259.
Patel J, Donovan P, Khosrotehrania K.Concise Review: Functional Definition of Endothelial Progenitor Cells: A Molecular Perspective.StemCells Translational Medicine. 2016;5:1302-1306.
M. Foster B , Zaidi D , R. Young T , E. Mobley M , A. Kerr B.CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.Biomedicines. 2018; 6(1):31
Harris KS , A. Kerr B.Prostate Cancer Stem Cell Markers Drive Progression,Therapeutic Resistance, and Bone Metastasis.Stem Cells International. 2017; 2017:8629234..
Corro C , Moch H. Biomarker discovery for renal cancer stem cells. The Journal of Pathology: Clinical Research. 2018;4:3-18.
Singh N, Xu H, Thiemann R, A. DeSantis K, Larsen M, E. LaFlamme S.Alpha 6 integrins promote cytokinesis by regulating the expression of RSK2 and MKLP1.bioRxiv. 2019.
Abderrazak A, El Azreq MA, Naci D, R. Fortin P , Aoudjit F. Alpha2beta1 Integrin (VLA-2) Protects Activated Human Effector T Cells From Methotrexate-Induced Apoptosis.Frontiers in Immunology. 2018; 9(2269): 1-12.
Kircher M, Herhaus P, Schottelius M , K. Buck A , A. Werner R, Wester HJ et al.CXCR4-directed theranostics in oncology and inflammation.Annals of Nuclear Medicine. 2018; 32: 503-511.
Basati G, Khaksarian M, Abbaszadeh S, Esmaeil Lashgarian H, Marzban A.Cancer stem cells and nanotechnological approaches for eradication.Stem Cell Investigation. 2019; 6 (38).
Natale B, Schweitzer C, Hughes M, A. Globisch M, Kotadia R, Tremblay E et al.Sca-1 identifies a trophoblast population with multipotent potential in the mid-gestation mouse placenta.scientific Reports. 2017;7(5575).
Komal Qureshi-Baig K, Ullmann P, Haan S , Letellier E.Tumor-Initiating Cells: a critical review of isolation approaches and new challenges in targeting strategies. Molecular Cancer. 2017; 16(40).
L. Wuebben E, Rizzino A.The dark side of SOX2: cancer - a comprehensive overview. Oncotarget. 2017; 8(27): 44917-44943.
Sin WC, Lim CL.Breast cancer stem cells—from origins to targeted therapy.Stem Cell Investigation. 2017; 4(96).
Hao L, Zhao Y, Wang Z, Yin H, Zhang X, He T et al. Expression and clinical significance of SALL4 and b-catenin in colorectal cancer.J Mol Hist. 2016.
Shi G, Jin Y. Role of Oct4 in maintaining and regaining stem cell pluripotency.Stem Cell Research & Therapy. 2010; 1(39).
Desai A , Yan Y, L. Gerson S.Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success. Stem Cells Translational Medicine. 2019; 8:75-81.
Kapoor P, J. Horsey A, H. Cox M , D. Kerr I. ABCG2: does resolving its structure elucidate the mechanism?. Biochemical Society Tranactions. 2018; 46:1485-1494.
- Muinao T, Deka Boruah HP, Pal M.Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells.Experimental Cell Research. 2018; 362:1-10.
Zhang B. CD73 promotes tumor growth and metastasis . OncoImmunology. 2012; 1(1): 67-70.
Ahmed M, Chaudhari K, Babaei-Jadidi R, V. Dekker L , Nateri A.S.Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells.Stem Cells . 2017; 35:839–850.
Ashrafizadeh M, Hushmandi K, Hashemi M, Akbari M.E, Kubatka P, Raei M et al. Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the metastasis of Bladder Cancer. Biomolecules. 2020;10(1159):1-26.
Song K.A, Faber A.C. Epithelial-to-mesenchymal transition and drug resistance:transitioning away from death. Journal of Thoracic Disease. 2019; 11(6): E82-E85.
Guo Q, Grimmig T, Gonzalez G, Giobbie-Hurder A, Berg G, Carr N et al. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer.J. Biol. Chem. 2018; 293(28):11166–11178.
J. Yoshida G, Saya H.Therapeutic strategies targeting cancer stem cells.Cancer Science. 2016; 107:5-11.
Roscigno G, Cirella A, Affinito A, Quintavalle C, Scognamiglio I, Palma F et al.miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. International Journal of Molecular Sciences. 2020; 21(2313).
Vander Linden C, Corbet C.Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche. Frontiers in Oncology. 2019; 9(159): 1-12.
Garza Treviño EN , Delgado González P, I C, Salgado V, Martinez Garza A.Effects of pericytes and colon cancer stem cells in the tumor microenvironment. Cancer Cell International. 2019; 19(173).
Zhou D, Shao L, R. Spitz D. Reactive Oxygen Species in Normal and Tumor Stem Cells. Adv Cancer Research. 2014;122: 1-67.
Ghahremani Farasfaji R, Bikhof Torbati M, Tafvizi F, Shaabanzadeh M. Cytotoxic Effect of Titanium Dioxide-Hydroxyurea Nanocamposit on Hela Cancer Cell Line. Journal of Babol University of Medical Sciences. 2019; 21: 116-121. [Full text In Persian].
Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K.Cyclooxygenase‐2 in cancer: A review. Journal of Cellular Physiology. 2018; 1-17.
Zhang S, Zhang R, Xu R, Shang J, He H, Yang Q. MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3).Gene. 2020; 733: 1-9.
Masoumi-Dehghi S, Babashah S, Sadeghizadeh M. microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways. Journal of Cell Communication and Signaling. 2020;14:233–44.
E. Drake L, Z. Springer M, P. Poole L, J. Kim C , F. Macleod K.Expanding perspectives on the significance of mitophagy in cancer.Sem. Cancer Biology. 2017; 47 :110-124.
Pellegrini P, Dyczynski M, Sbrana FV, Karlgren M, Buoncervello M, Hägg-Olofsson M et al. Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. Oncotarget. 2016; 7(24): 35703-35723.
Smith AG , Macleod KF.Autophagy, cancer stem cells and drug resistance. Journal of Pathology. 2019; 247:708-718.
Ferreira JA, Peixoto A, Neves M, Gaiteiro C, A. Reis C, G. Assaraf Y et al. Mechanisms of Cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.Drug Resist Updat. 2016;24: 34-54.
Wang MC, Li CL, Cui J, Jiao M, Wu T, Jing L et al.BMI 1, a promising therapeutic target for human cancer. Oncology Letters. 2015; 10: 583-588.
Chen D, Wu M, Li Y, Chang I, Yuan Q, Ekimyan-Salvo M et al.Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.Cell Stem Cell. 2017; 20: 1-14.
Zhang GF, Li CX, Liu ZQ, Ma S, Chen HB. Cancer stem cell targets - a review. European Review for Medical and Pharmacological Sciences. 2016; 16:2045-2051.
Ragusa S, Prat-Luri B, Gonzalez-Loyola A, Nassiri S, Squadrito ML, Guichard A et al.Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. The Journal of Clinical Investigation. 2020; 130(3): 1199-1216.
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J et al.Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy. 2020; 5(8).
Cazet, A.S., Hui, M.N., Elsworth, B.L., Wu S, Roden D, Chan CL et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications. 2018; 9(2897): 1-18.
Green R, Howell M, Khalil R, Nair R, Yan J, Foran E et al. Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway. Scientific Reports. 2019; 9(18177): 1-13.
Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Jr PNL et al.Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014; 33: 4521-4530.
Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine.2016; 95(S1): S20–25.
Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Cancer. 2012; 12:252-264.
Nankali E, Shaabanzadeh M , Bikhof Torbat M. Fluorescent tamoxifen-encapsulated nanocapsules functionalized with folic acid for enhanced drug delivery toward breast cancer cell line MCF-7 and cancer cell imaging. Naunyn-Schmiedeberg's Archives of Pharmacology. 2020; 393(7):1211-1219
Papaliagkas V, Anogianaki A, Anogianakis G, Ilonidis G. The proteins and the mechanisms of apoptosis:A mini-review of the fundamentals. HIPPOKRATIA. 2007; 11(3): 108-113.
Busca A, Saxena M, Kryworuchko M, Kumar A. Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection. Current Genomics. 2009;10(5): 306-317.
Mojibi P, Tafvizi F, Bikhof Torbati M. Cell-bound Exopolysaccharide Extract from Indigenous Probiotic Bacteria Induce Apoptosis in HT–29 cell-line. Iranian Journal of Pathology. 2019; 14(1): 41-51.
Khakrizi E, Bikhof Torbati M, Shaabanzadeh M. The Study of Anticancer Effect of Magnetic Chitosan-Hydroxyurea Nanodrug on HeLa Cell line: A Laboratory Study. Journal of Rafsanjan University of Medical Sciences. 2018; 17(8): 715-30. [Full text in Persian].
Sun H.R, Wang S, Yan S.C, Zhang Y, Nelson P.J, Jia H.L, Qin L.X, Dong Q.Z. Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Frontiers in Oncology. 2019; 9(1104): 1-14.
Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells International.2016; 18:1-16.
Oei A.L, Vriend L.E.M, Krawczyk P.M, Horsman M.R, Franken N.A.P , Crezee J. Targeting therapy-resistant cancer stem cells by hyperthermia. International Journal of Hyperthermia. 2017; 33(4):419-427.
Fan X, He D, Sheng CB, Wang B, Wang LJ, Wu XQ et al. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. Am. J .Transl. Res. 2019; 11(6):3543-3554.
Kwiatkowska-Borowczyk E, Gąbka-Buszek A, Jankowski J, Mackiewicz A.Immunotargeting of cancer stem cells. Contemporary Oncology. 2015; 19(1A):A52-A59.
Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y et al. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. STEM CELLS. 2015; 33:2085-2092.
Carnero A , Garcia-Mayea Y , Mir C , Lorente J , Rubio IT , Lleonart ME. Anti-Tumor Treatment, The cancer stem-cell signaling network and resistance to therapy. Cancer Treatment Reviews. 2016; 49: 25-36.
Li Y, Zhong W, Zhu M, Li M, Yang Z.miR-185 inhibits prostate cancer angiogenesis induced by the nodal/ALK4 pathway. BMC Urology. 2020; 20(49).
Mu HQ, He YH, Wang SB, Yang S, Wang YJ, Nan CJ et al.MiR 130b/TNF α/NF κB/VEGFA loop inhibits prostate cancer angiogenesis. Clinical and Translational Oncology. 2019; 1: 111-121.
Pützer B , Solanki M, Herchenröder O.Advances in cancer stem cell targeting: How to strike the evil at its root. Advanced Drug Delivery Reviews. 2017; 120:89-107.
Annett S, Moore G, Short A, Marsha A, McCrudden C, Yakkundi A et al. FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer. 2020; 126: 361.
Wang M, Zeng Q, Li Y, Imani S, Xie D, Li Y et al. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. Journal of Drug Targeting. 2020; 28(9): 961-969.
Sohrabi M, Amirnasr M, Meghdadi S, Lutz M, Bikhof Torbati M, Farrokhpour H. A highly selective fluorescence turn-on chemosensor for Zn 2+, and its application in live cell imaging and as a colorimetric sensor for Co2+: Experimental and TD-DFT calculations. New.J.Chem. 2018; 42: 12595-12606.
Rahimnejad S, Bikhof Torbati M. Synthesis of Hydroxyapatite/Ag/TiO2 Nanotubes and Evaluation of Their Anticancer Activity on Breast Cancer Cell Line MCF-7.Journal of Chemical Health Risks. 2016; 6(3): 1-10.
- Abstract Viewed: 187 times
- PDF Downloaded: 158 times